glp-1 for fibromyalgia and Semaglutide: Patient Outcomes Episode 131: GLP-1 Medications with

But the small sample size and the lifestyle factor mean its hard to know how much of the effect is the ingredient itself

Throughout the study, changes in body measurements, blood glucose, triglyceride, and cholesterol levels were monitored at regular intervals

Key highlights Tirzepatide is the first dual GLP-1/GIP receptor agonist that offers stronger appetite suppression, improved glycemic control, and provides significantly greater weight loss than single receptor agonists such as semaglutide, liraglutide, and dulaglutide

doi: 10.1007/s00125-021-05541-0

The analysis concluded that Tirzepatide, particularly at higher doses, provides the greatest weight reduction in adults without diabetes